Bel EH, et al. - In this open-label, single-arm, Phase IIIa study, researchers assessed if mepolizumab could be successfully self-injected via prefilled syringe (PFS) by patients with severe eosinophilic asthma (SEA), or their caregivers, in clinic and at home. SEA patients (aged ≥12 years) on mepolizumab (100 mg subcutaneously administered every 4 weeks for ≥12 weeks before screening) were included, as well as those having SEA not receiving mepolizumab at screening but met additional criteria. The study was completed by 55 of the 56 patients/caregivers who self-administered ≥1 dose of mepolizumab. Via the PFS, successful self-administration of mepolizumab by patients/caregivers was reported both in clinic and at home, without any new safety concern.